[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100380293":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":36,"centralContacts":36,"locations":50,"responsibleParty":64,"collaborators":36,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":36,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":36,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":36,"overallStatus":87,"whyStopped":36,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Wayne State University","OTHER",[8,15,21,26],{"label":9,"type":10,"description":11,"interventionNames":12},"placebo stressor, sham rTMS","PLACEBO_COMPARATOR","Placebo stressor (lactose) + sham (inactive) rTMS over the left dlPFC",[13,14],"Drug: Placebo","Device: Sham rTMS",{"label":16,"type":17,"description":18,"interventionNames":19},"placebo stressor, active rTMS","EXPERIMENTAL","Placebo stressor (lactose) + active 10Hz rTMS over the left dlPFC",[20,13],"Device: Active rTMS",{"label":22,"type":17,"description":23,"interventionNames":24},"active stressor, sham rTMS","Stressor (yohimbine 54mg + hydrocortisone 20mg) + sham (inactive) rTMS over the left dlPFC",[25,14],"Drug: Yohimbine + Hydrocortisone",{"label":27,"type":17,"description":28,"interventionNames":29},"active stressor, active rTMS","Stressor (yohimbine 54mg + hydrocortisone 20mg) + active 10Hz rTMS over the left dlPFC",[25,20],[31,37,42,46],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","Yohimbine + Hydrocortisone","Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)",[27,22],null,{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":36},"DEVICE","Active rTMS","10Hz rTMS over the left dlPFC",[27,16],{"type":32,"name":43,"description":44,"armGroupLabels":45,"otherNames":36},"Placebo","lactose (inside capsule)",[16,9],{"type":38,"name":47,"description":48,"armGroupLabels":49,"otherNames":36},"Sham rTMS","inactive stimulation over the left dlPFC",[22,9],[51],{"facility":52,"status":36,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":36},"Tolan Park Medical Building","Detroit","Michigan","48201","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-83.04575,42.33143,{"lat":62,"lon":61},{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"PRINCIPAL_INVESTIGATOR","Mark Greenwald, PhD","Principal Investigator","100380293","phase-2-effects-of-pharmacological-stress-and-rtms-on-executive-function-in-opioid-use-disorder-100380293",false,"NCT04231708","Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder","Effects of Pharmacological Stress and Repetitive Transcranial Magnetic Stimulation Interventions on Executive Function in Opioid Use Disorder","Inclusion Criteria:\n\n* Meet DSM-5 criteria for OUD;\n* Age 21-60 yr;\n* Right handed;\n* Males and non-pregnant\u002Fnon-lactating females;\n* cognitively intact (total IQ score \\>80 on Shipley Institute of Living Scale);\n* Screening cardiovascular indices within ranges for safe use of the pharmacological stressor: resting HR 50-90 bpm, systolic BP 90-140 mmHg, and diastolic BP 50-90 mmHg;\n* Use alcohol and\u002For marijuana \\\u003C3 times\u002Fweek; each \"time\" should consist of \\\u003C1 marijuana \"joint\" equivalent and \\\u003C3 alcoholic drinks.\n\nExclusion Criteria:\n\n* Under influence of any substance during session;\n* Past 7-day use of illicit drugs other than opioids (except marijuana, which is legal in Michigan);\n* Urinalysis positive for cocaine metabolites, benzodiazepines, barbiturates, amphetamines or pregnancy;\n* Medical conditions prohibiting use of rTMS (e.g. seizure history; based on rTMS screening questionnaire);\n* Lifetime diagnosis of: psychotic disorder, bipolar disorder, generalized anxiety disorder, or obsessive compulsive disorder; major depression in the past 5 years; or potentially antisocial personality disorder (if the clinical psychologist judges such behaviors to be potentially disruptive or unsafe in our lab);\n* Past-year SUD other than OUD;\n* Acute\u002Funstable illness: conditions making it unsafe for participation (e.g. neurological, cardiovascular, pulmonary, or systemic diseases);\n* Lactose intolerance (placebo dose);\n* Any prohibited medications: medications that lower seizure threshold, psychiatric medications, prescription pain medications, or blood pressure medications;\n* Chronic head or neck pain; and\n* Past-month participation in a research study.","ALL","21 Years","60 Years",{"count":79,"type":80},20,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","This preliminary study is designed to evaluate mechanisms by which excitatory dorsolateral prefrontal cortex (dlPFC) repetitive transcranial magnetic stimulation (rTMS) (vs. sham) and pharmacological stress (vs. placebo) alter behavior in non-treatment seeking individuals with opioid use disorder (OUD). Specific Aims are to (1) Evaluate how stress impacts domains of behavior including (1a) executive function and (1b) opioid-seeking behavior; and (2) Determine whether rTMS stimulation attenuates (2a) executive dysfunction, (2b) stress-reactivity, and (2c) opioid-seeking in individuals with OUD not receiving treatment.",[86],"Opioid Use Disorder","NOT_YET_RECRUITING","2025-12-26",{"date":90,"type":91},"2025-12-30","ACTUAL",{"date":93,"type":80},"2026-10",{"date":95,"type":80},"2028-12",{"name":5,"class":6},1]